TABLE 1.
Baseline characteristics and drug treatment of patients.
| CAL (N = 40) | NCAL (N = 39) | P value | |
|---|---|---|---|
| Age, mon | 21.7 (8.2–30.9) | 23.7 (9.0–40.0) | 0.372 |
| Sex, male | 29 (72.5%) | 28 (71.8%) | 0.944 |
| Medication | |||
| IVIG, 2 g/kg*1 d | 35 (87.5%) | 38 (97.4%) | 0.096 |
| IVIG, 1 g/kg*2 days | 5 (12.5%) | 1 (2.6%) | 0.096 |
| Aspirin | 38 (95%) | 38 (97.4%) | 1.000 |
| Persantine | 29 (72.5%) | 15 (38.5%) | 0.002 |
| Complications | 25 (62.5%) | 25 (64.1%) | 0.883 |
| Liver function damage | 7 (17.5%) | 7 (17.9%) | 0.958 |
| Granulocytopenia | 8 (20%) | 5 (12.8) | 0.390 |
| URI | 3 (7.5%) | 4 (10.3%) | 0.972 |
| LRI | 8 (20%) | 4 (10.3%) | 0.228 |
| WBC, 109/L | 16.4 ± 6.8 | 15.8 ± 7.2 | 0.368 |
| PLT, 109/L | 392.7 ± 115.9 | 374.2 ± 118.1 | 0.704 |
| CRP, mg/L | 75.94 ± 53.6 | 71.1 ± 51.9 | 0.395 |
| ESR, mm/h | 33.0 ± 12.0 | 31.8 ± 10.3 | 0.443 |
| BNP, pg/mL | 1505.0 (455.0–3557.5) | 833.5 (318.5–2315.0) | 0.192 |
| ALT, U/L | 50.0 (17.0–115.0) | 54.0 (22.0–109.0) | 0.734 |
| AST, U/L | 35.5 (23.8–51.0) | 29.0 (25.0–35.0) | 0.294 |
| TG,mmol/L | 1.29 ± 0.3 | 1.3 ± 0.46 | 0.972 |
| TC,mmol/L | 3.56 ± 0.73 | 3.61 ± 0.63 | 0.701 |
| HDL-C,mmol/L | 1.8 ± 0.75 | 2.35 ± 0.55 | 0.043 |
| LDL-C.mmol/L | 2 ± 0.84 | 1.21 ± 0.83 | 0.000 |
Data are presented as the mean ± SD, n (%) or medians (interquartile ranges). CAL, coronary artery lesion; NCAL, non-coronary artery lesion; IVIG, intravenous immunoglobulin; URI, upper respiratory infection; LRI, lower respiratory infection; WBC, white blood cell; PLT, platelet; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; BNP, brain natriuretic peptide; ALT, alanine transaminase; AST, aspartate aminotransferase; TG, triglycerides; TC, total cholesterol; HDL-C, high density lipoprotein; LDL-C, low density lipoprotein.